W

Wellington Management

Global asset management for institutional clients

Equity Research Associate - Asia Financials

Full-TimeUpdated on 10/15/2026
No salary listed
Mid, Senior
Bachelor's
Singapore
HybridEmployees work in the office four days a week and may work remotely one day a week.
Finance & BankingEquity & Credit Research

About the job

Requirements
  • An undergraduate degree and a strong academic record.
  • Approximately 3–5 years of relevant professional experience in buy-side or sell-side equity research.
  • Strong financial modelling and analytical skills, including effective use of AI and other investment research tools to enhance the research process.
  • A disciplined, bottom-up approach to fundamental investment research.
  • Ability to work independently, exercise sound judgement, and make decisions under uncertainty.
  • Strong interpersonal skills and ability to build trusted relationships and collaborate across experienced, cross-functional investment teams.
  • Strong organisational skills and ability to manage multiple priorities effectively.
  • Full fluency in spoken and written English.
  • Sound judgement, a strong work ethic, and high standards of personal and professional integrity.
  • Intellectual humility, resilience, and willingness to challenge existing views and learn from mistakes.
  • Exceptional attention to detail.
  • Commitment to continuous learning and professional development.
Responsibilities
  • Conduct ongoing fundamental research and due diligence on companies across the Asia financials sector, maintaining a deep understanding of industry developments, competitive dynamics, and investment implications.
  • Develop and maintain detailed financial models, valuation frameworks, peer analysis, and industry knowledge to support analysis of existing holdings and prospective investment opportunities.
  • Attend company meetings, industry conferences, and other relevant events to develop differentiated insights into emerging industry trends, structural changes, and investment opportunities.
  • Partner with the Global Industry Analyst to translate insights into actionable research and investment recommendations.
  • Prepare high-quality written research and communicate investment recommendations to the Global Industry Research Financials team and the broader investment platform.
Desired Qualifications
  • CFA designation or progress toward completing the CFA Program.
  • Experience covering the Financials sector.
  • Mandarin proficiency.

About the company

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$65.7B

Headquarters

Boston, Massachusetts

Founded

1933

Get referred to Wellington Management

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Hartford Funds acquisition closes in first quarter 2027, adding wealth distribution.
  • The new Wellington-Vanguard-Blackstone solutions expand access to public-private portfolios.
  • Wellington’s venture, biotech, climate, and CLO launches broaden fee-bearing alternatives.

What critics are saying

  • Hartford Funds integration carries execution risk until regulators approve the Q1 2027 close.
  • Steve Klar’s retirement in June 2026 exposes client-platform succession risk.
  • Passive giants and private-credit rivals compress Wellington’s fees and threaten AUM growth.

What makes Wellington Management unique

  • Wellington blends public and private markets through alliances with Vanguard and Blackstone.
  • Its $1.35 trillion platform spans 60 countries and over 2,500 institutional clients.
  • Matt Witheiler’s Forbes Midas List streak validates Wellington’s late-stage growth investing credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Business Wire
Oct 13th, 2026
Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program

Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing orally bioavailable, small molecule therapies for musculoskeletal diseases, toda...

MarketScreener
Oct 13th, 2026
Alaunos Therapeutics to raise $350M in private placement led by Fairmount

Alaunos Therapeutics has agreed to raise about $349.95 million through a private placement of stock. It signed a Securities Purchase Agreement to sell 687,789 shares of common stock at $1.4357 per share and 243,063 shares of Series C preferred stock at $1,435.70 per share. The common stock brings in about $987,459, and the preferred stock about $348.97 million. The deal is expected to close on October 14, 2026, subject to customary closing conditions. Fairmount led the placement of Series C non-voting convertible preferred stock. Venrock Healthcare Capital Partners, T. Rowe Price Investment Management, Wellington Management, Janus Henderson Investors, Access Biotechnology, BB Biotech, Perceptive Advisors, Sirenia Capital Management, ADAR1 Capital Management and other firms took part.

LinkedIn
Sep 30th, 2026
We just closed an employee tender offer which values ElevenLabs at $22BN, up 2x from our Series D in February. The tender was led by Wellington and T. Rowe Price, and the growth is driven by demand… | Mati Staniszewski | 89 comments

We just closed an employee tender offer which values ElevenLabs at $22BN, up 2x from our Series D in February. The tender was led by Wellington and T. Rowe Price, and the growth is driven by demand from enterprises to deploy ElevenAgents across sales, support, and operations. In 2022, we raised our first round at a $9 million valuation, which we announced alongside Eleven v1, our first Text to Speech model, and the first model to generate human-level speech. Four years later, as we reach our new valuation, we just released two new state-of-the-art Text to Speech models. Eleven v4 and v4 Turbo are our fastest and most emotive models yet, and are leading independent benchmarks. Alongside models, we have built a full interaction platform for AI. It allows organizations to deploy conversational agents, connected to their knowledge and systems, that interact naturally in any industry, geography, or context. This shift is driving much of our growth, with enterprise now accounting for 55% of our revenue, as businesses adopt ElevenAgents to support their customers and employees. Our technology is now used in daily operations at five of the world’s ten largest tech companies, five of the ten largest insurers, and four of the ten largest telecoms. The round was co-led by Wellington Management and T. Rowe Price, along with participation from Goldman Sachs, GIC, Ontario Teachers'​ Pension Plan, EQT Group, Sapphire Ventures, and BDT & MSD Partners. And grateful for ongoing support from existing investors including Andreessen Horowitz, Alkeon Capital, The D. E. Shaw Group, Disruptive, Evantic Capital, ICONIQ, and Lightspeed. Most of all, this round is for the team that built the last four years. We're just getting started! | 89 comments on LinkedIn

MarketScreener
Sep 29th, 2026
Immix Biopharma prices $125M stock offering to fund AL amyloidosis therapy development

Immix Biopharma has priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share, expecting gross proceeds of $125 million before deducting underwriting discounts and expenses. The offering is expected to close on or about 30 September 2026. The company intends to use the net proceeds to fund development of NXC-201, working capital, and general corporate purposes. NXC-201 is a CAR-T cell therapy being evaluated for relapsed/refractory AL Amyloidosis and has received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation from the US FDA. J.P. Morgan is acting as sole book-running manager. The offering included participation from institutional investors including Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments, and Wellington Management.

Yahoo Finance
Sep 14th, 2026
Temporal raises $550M at $12.55B valuation as AI infrastructure demand surges

Temporal has raised $550 million in Series E funding at a $12.55 billion valuation, led by Lightspeed Venture Partners. Co-leads include Wellington Management, Growth Equity at Goldman Sachs Alternatives, and Tiger Global. The open-source platform, which powers AI applications, has seen significant growth in 2026. Its annualised revenue run rate recently surpassed $250 million, growing more than 200% year-over-year. Net dollar retention has exceeded 200% since February. Temporal Cloud processed 1.9 trillion actions in August, up more than 350% year-over-year. Open-source installs surpassed 43 million in August, up 134% since January 2026. The company now has more than 4,300 paying customers, including OpenAI, Snap, NVIDIA, Netflix, and JPMorgan Chase. Temporal provides infrastructure for reliable execution of critical applications, from payments to autonomous AI agents.